Researchers present new techniques for early diagnosis and treatment of lung cancer, improving 5-year survival rates from 10% to 70%. A new factor that correlates with clinical parameters may also help indicate patient prognosis.
Researchers are exploring new treatments for lung cancer using targeted therapies and personalized care. Studies have shown promising results in improving patient outcomes, including the use of molecular targeted therapies and chemotherapy combinations.
Cancer patients experiencing malnutrition are at a higher risk of psychological distress. Researchers found that the level of distress is positively correlated with nutritional status, highlighting the need for evaluation of nutrition in cancer care.
According to the study, approximately half of patients with early-stage laryngeal cancer who undergo radiotherapy develop malnutrition, defined as weight loss of at least 5%. Patients with neck lymph node irradiation are more than four times as likely to become malnourished.
A recent study found that early detection of second breast cancers in women who have already had the disease can significantly improve their chances of survival. The research revealed that mammography was more sensitive than clinical examination for detecting second cancers, with a sensitivity of 86%. Early detection at an asymptomatic...
In a phase II trial, pazopanib was found to shrink lung cancer tumors in 30 out of 35 patients by up to 85%. The results suggest that pazopanib is highly active in early stage operable lung cancer. Further development of this drug in lung cancer is underway.
Genetic testing identifies patients with advanced colorectal cancer who are likely to survive longer on cetuximab, a new standard of care for targeted therapies. Tumor cell analysis also reveals high levels of circulating cells before treatment as an indicator of disease aggressiveness.
Multidisciplinary approaches combining chemotherapy, radiotherapy, and surgery have shown promise in treating various cancers, including lung and head and neck cancers. The addition of targeted therapies like pazopanib and cetuximab has demonstrated significant activity in reducing tumor size and improving patient outcomes.
A new chemotherapy drug combination has shown excellent results in a phase II trial, extending median survival time in patients with inoperable pancreatic cancer by up to 6.4 months compared to standard therapy. The treatment, EndoTAG-1, destroys new blood vessels around tumors, improving patient outcomes.
A genetic variant in the cyclin D1 gene is associated with a higher risk of developing melanoma. Individuals carrying two copies of the variant are 80% more likely to develop the disease. Extended and escalated dose chemotherapy shows no survival benefit in advanced melanoma cases.
A study at ESMO found gefitinib to be more tolerable and result in a greater likelihood of response in non-smoking Asian patients with adenocarcinoma of the lung. The targeted therapy is now considered a first-line treatment for this population.
Adding intravenous iron to chemotherapy-induced anemia treatment boosts response rates by up to 50% and reduces treatment duration, according to a new study. Lower doses of darbepoetin alfa also show improved results with the addition of iron therapy.
A phase II trial of the investigational drug pazopanib has shown promising results in treating ovarian cancer. The study found that 31% of patients experienced a significant decrease in CA-125 levels, with a median duration of response of 113 days.
A study by the European Society for Medical Oncology found substantial variation in the uptake of newer cancer drugs across EU countries. The cost of these drugs is a major barrier to access, and their complexity can make them harder to understand and use effectively.
Research reveals pegylated liposomal doxorubicin delays disease progression while minimizing toxicity, with a low risk of serious side effects such as cardiotoxicity or mucositis. The treatment improves time-to-progression and overall survival in metastatic breast cancer patients.
A new combination therapy of trabectedin and pegylated liposomal doxorubicin shows clinical benefit for women with relapsed ovarian cancer. The treatment offers an alternative to traditional platinum-based regimens, providing a fresh option for those whose cancer recurs after first-line treatment.
Researchers found that adding four cycles of Taxotere to a sequential regimen of epirubicin and cyclophosphamide, methotrexate and fluorouracil reduces recurrence and death rates in patients with node-positive early stage breast cancer. This advantage comes at an increased toxicity level.
A phase II trial involving 45 patients found that an alternating regimen of chemotherapy and radiotherapy, plus cetuximab, yields favorable complete response rates and long-term results comparable to the best reported in literature. However, skin toxicity and toxicities resulting in patient deaths were also observed.
Researchers found that patients with specific EGFR gene mutations can live almost two years on average when treated with erlotinib, outperforming chemotherapy by two-to-three fold. The study identified a subgroup of 15-22% patients who can benefit from targeted therapies
Researchers at ESMO Conference Lugano report improved treatment outcomes for aggressive non-Hodgkin's lymphoma patients when chemotherapy is administered every 2 weeks, rather than every 3 weeks.
Researchers found that circulating tumor cell counts accurately predict treatment response and survival in castration-resistant prostate cancer. Patients with declining cell counts showed improved prognosis, reflecting potential therapy benefits.
Men with breast cancer often experience poor outcomes due to delayed diagnoses, with 50% of cases reaching advanced stages. Early detection and treatment are crucial, as hormone therapy can be highly effective in treating the disease.
Research suggests common viruses, such as human papillomavirus (HPV) and measles virus, may play a role in lung cancer development, particularly in smokers. Studies have found that five out of 22 non-small-cell lung cancer samples were positive for HPV.
Researchers have developed a test to accurately distinguish between squamous and non-squamous forms of non-small-cell lung cancer based on microRNA levels. This method can improve diagnosis and treatment guide for patients with the disease.
A new online database provides a comprehensive list of somatic EGFR mutations, allowing clinicians to make more robust decisions about treatment options for non-small-cell lung cancer patients. The database includes data from thousands of patients and offers improved treatment outcomes for those receiving tyrosine kinase inhibitors.
A new clinical trial found that MAGE-A3 ASCI reduces the risk of lung cancer relapse after surgery, similar to chemotherapy but with fewer side effects. The treatment, which boosts the immune system, showed minimal reactions at injection sites and was suitable for long-term maintenance treatment.
A clinical trial evaluating sorafenib added to carboplatin/paclitaxel chemotherapy for lung cancer patients showed the combination offers no improved overall survival. Sorafenib results in worse outcomes for some patients with squamous histology.
A growing trend of premature trial stops is raising concerns about patient safety and the over-statement of treatment effects. Italian researchers analyzed 25 trials that stopped due to patient benefits, finding that most were linked to marketing applications, potentially prioritizing industry interests.
A new study found that while MRI has a high false positive rate, it still detects genuine breast cancer cases effectively. However, the rate of false positives does not impact a woman's decision to undergo prophylactic mastectomy.
A study found that many cancer patients with metastatic disease incorrectly believe opioids are only for dying patients. Morphine can improve pain management and quality of life for living patients. Experts stress the importance of professional confidence in opioid use to change these beliefs.
A leading epidemiologist attacks a Swedish research report on cancer drug access, citing flawed methods, incorrect conclusions, and potential industry influence. The Karolinska report aimed to link national cancer survival rates with access to cancer drugs, but its methodology has been disputed.
A new drug candidate, abiraterone, has shown significant anti-tumor activity in early trials for patients with advanced prostate cancer whose tumors have continued to grow despite medical or surgical castration. The drug reduced PSA levels and shrunk tumors in both pre- and post-chemotherapy patients.
A recent meta-analysis confirms that combining trastuzumab with chemotherapy reduces mortality by -34% and increases disease-free survival by 38% in women with operable HER-2 positive breast cancer. This treatment strategy also decreases the risk of locoregional and distant recurrences.
Researchers have found a new virus, NV1020, to be effective against colorectal cancer with minimal side effects. The treatment has shown promising results in reducing tumor masses and improving patient survival.
Cancer is a major cause of disease and mortality worldwide, requiring a strong political signal for alliance and concerted actions. The Round Table on Health Strategies in the European Union will focus on creating capacity building for effective policies and programs to address cancer.
The Netherlands Cancer Institute received the ESMO Lifetime Achievement Award for its outstanding contributions to translational research in breast cancer. The team's discovery of a gene-signature has led to improved prognostic testing and reduced adjuvant chemotherapy in pre-menopausal patients.
A new study found that only 9% of breast cancer specialists adhere to guidelines for follow-up care, with varying frequencies of mammograms and discharge times. The research highlights the need for improved coordination between specialists and general practitioners to provide better patient care.
A report by European Society for Medical Oncology reveals stark inequalities in access to cancer treatment globally. Key findings include that Austria, France, and the US have high uptake of new cancer drugs, while countries like New Zealand, Poland, and South Africa have low uptake.
The collaboration aims to broaden the scientific basis for targeted cancer therapies, combining expertise from NDDO, ESMO, and NCI. The partnership will further accelerate early-phase clinical trials and translational research, strengthening ties between European and US cancer research communities.
A new report by the European Society for Medical Oncology warns that Europe's aging population is driving a major increase in cancer cases and deaths. The report estimates that there were 3.2 million new cancer cases diagnosed in 2006, with lung cancer remaining the leading cause of death.
A Canadian oncologist warned doctors to be aware of the potential risk of suicide among cancer patients. The study found that American cancer patients are more than twice as likely to kill themselves as the general population. The risk varies according to factors such as gender, prognosis, and type of cancer.
A study of children and young adults treated with doxorubicin for bone tumors found progressive worsening of heart damage, with nearly half showing diastolic dysfunction. Regular echocardiography is recommended to monitor heart function and prevent further deterioration.
The ASCO and ESMO have released a consensus statement outlining 10 essential components of quality cancer care, aiming to address inequalities in healthcare systems worldwide. The document highlights the importance of informed consent, multidisciplinary care teams, and access to innovative treatments for patients diagnosed with cancer.
Fenretinide has been shown to reduce the risk of second breast cancers in young women, particularly those under 40. The study found a 38% reduction in second breast cancers in pre-menopausal women and halved the risk for women under 40.
Researchers found a statistically significant direct relationship between high cholesterol and prostate cancer. Men with prostate cancer were around 50% more likely to have had high cholesterol levels than non-prostate cancer controls, especially those diagnosed before age 50 or over 65.
A study has found that vaginal oestrogen can increase systemic oestradiol levels in women on aromatase inhibitors (AI) for breast cancer, potentially counteracting AI treatment. Researchers recommend avoiding the combination of AIs and vaginal oestrogens, except in exceptional circumstances.
New research suggests that Herceptin may be cost-effective for certain sub-groups of patients with early breast cancer, but its use as adjuvant therapy could impose a significant financial burden on healthcare systems. The study estimates that the cost of providing Herceptin treatment in Belgium would be around €25.5 million per year.
A study of 208 women with early or advanced breast cancer found that nearly half forgot their tablets and over a tenth deliberately skipped doses. The research highlights the need for doctors to address patients' concerns about hot flushes and injections, which can affect treatment adherence.
A new report by the European Society for Medical Oncology reveals that female lung cancer death rates in Europe are still rising, despite a 16% increase between 1990-2001. However, trends in some countries and among younger women show a decline, suggesting future hope for reducing this epidemic.
A study of 60 male and 4,181 female breast cancer patients found that men were almost six times more likely to receive radiotherapy than women with similar disease stages. The researchers concluded that men should be treated using the same guidelines as women for radiotherapy treatment.